Evaluation of Ouabain's Tissue Distribution in C57/Black Mice Following Intraperitoneal Injection, Using...

Area of Science:

• Pharmacology
• Neuroscience
• Cardiology

Background:

• Cardiotonic steroids (CTSs) like digoxin are vital for heart failure treatment.
• Digoxin's ability to cross the brain-blood barrier (BBB) can lead to central nervous system (CNS) side effects.
• Developing BBB-impermeable CTSs is crucial for enhanced clinical applicability and reduced CNS risks.

Purpose of the Study:

• To investigate the tissue distribution of ouabain after intraperitoneal injection in mice.
• To determine if ouabain penetrates the BBB.

Main Methods:

• Ouabain concentrations were measured in brain, heart, liver, kidney tissues, and plasma of C57/black mice post-injection using HPLC-MS.
• Measurements were taken at multiple time points (5 min to 24 h) after a 1.25 mg/kg intraperitoneal dose.

Main Results:

• Ouabain was undetectable in brain tissue, indicating it does not cross the BBB.
• Ouabain showed rapid elimination from plasma and cardiac tissue.
• High concentrations were observed in kidney and liver tissues, with varying elimination rates.

Conclusions:

• Ouabain does not cross the BBB in mice, differentiating it from digoxin.
• Ouabain's rapid systemic elimination suggests potential advantages for systemic administration in heart failure.
• Intracerebral administration is necessary for studying ouabain's CNS effects due to its BBB impermeability.